Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial
European Journal of Cancer · 2023
DOI: 10.1016/j.ejca.2023.113336 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift European Journal of Cancer, 2023. Verfasst von Shan-Shan Guo und 22 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovati…. Hauptthemen laut MEDLINE: Nasopharyngeal Neoplasms, Epstein-Barr Virus Infections, Radiotherapy, Intensity-Modulated. Die Arbeit wurde bisher 37-mal zitiert (Crossref) und nennt 32 Literaturangaben.
Abstract (Originalsprache)
BACKGROUND: Radiotherapy-related toxicities of nasopharyngeal carcinoma (NPC) caused by a standard dose of 70 Gy remain a critical issue. Therefore, we assessed whether a radiotherapy dose of 60 Gy was non-inferior to the standard dose in patients with low-risk stage III NPC with a favourable response to induction chemotherapy (IC). PATIENTS AND METHODS: We did a single-arm, single-centre, phase II clinical trial in China. Patients with low-risk (Epstein-Barr virus [EBV] DNA level
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nasopharyngeal Carcinoma, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyng…
- Department of Radiology, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma D…
- Clinical Trials Center, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Guangdong Key Laboratory of Nasopharyngeal Carcinoma Di…
Zitieren
APA
Guo, S. S., Yang, J. H., Sun, X. S., Liu, L. Z., Yang, Z. C., Liu, L. T., Liu, S. L., Li, X. Y., Lv, X. F., Luo, D. H., Li, J. B., Liu, Q., Wang, P., Guo, L., Mo, H. Y., Sun, R., Yang, Q., Liang, Y. J., Jia, G. D., …, & Mai, H. Q. (2023). Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2023.113336
Vancouver
Guo SS, Yang JH, Sun XS, Liu LZ, Yang ZC, Liu LT, et al. Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial. European Journal of Cancer. 2023. doi:10.1016/j.ejca.2023.113336
BibTeX
@article{Guo2023,
author = {Guo, Shan-Shan and Yang, Jin-Hao and Sun, Xue-Song and Liu, Li-Zhi and Yang, Zhen-Chong and Liu, Li-Ting and Liu, Sai-Lan and Li, Xiao-Yun and Lv, Xiao-Fei and Luo, Dong-Hua and Li, Ji-Bin and Liu, Qing and Wang, Pan and Guo, Ling and Mo, Hao-Yuan and Sun, Rui and Yang, Qi and Liang, Yu-Jing and Jia, Guo-Dong and Zhao, Chong and Chen, Qiu-Yan and Tang, Lin-Quan and Mai, Hai-Qiang},
title = {Reduced-dose radiotherapy for Epstein-Barr virus DNA selected staged III nasopharyngeal carcinoma: A single-arm, phase 2 trial},
journal = {European Journal of Cancer},
year = {2023},
doi = {10.1016/j.ejca.2023.113336}
}
EUVIMED